Novo Nordisk announced that the European Commission has granted marketing authorisation for Fiasp® for the treatment of diabetes in adults. The authorisation covers all 28 European Union member states. Fiasp® is the brand name for fast-acting insulin aspart. Fiasp® provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid®. Fiasp® will be available in vial, Penfill® and FlexTouch® pen. Novo Nordisk expects to launch Fiasp® in the first European countries in the first half of 2017.